Citius Pharmaceuticals Statistics
Total Valuation
CTXR has a market cap or net worth of $7.37 million. The enterprise value is $6.47 million.
Important Dates
The next estimated earnings date is Friday, May 16, 2025, after market close.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CTXR has 9.83 million shares outstanding. The number of shares has increased by 13.45% in one year.
| Current Share Class | 9.83M |
| Shares Outstanding | 9.83M |
| Shares Change (YoY) | +13.45% |
| Shares Change (QoQ) | +3.57% |
| Owned by Insiders (%) | 7.68% |
| Owned by Institutions (%) | 6.29% |
| Float | 9.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 0.08 |
| PB Ratio | 0.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.41, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.41 |
| Quick Ratio | 0.02 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.48% and return on invested capital (ROIC) is -34.46%.
| Return on Equity (ROE) | -52.48% |
| Return on Assets (ROA) | -24.47% |
| Return on Invested Capital (ROIC) | -34.46% |
| Return on Capital Employed (ROCE) | -56.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.77M |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CTXR has paid $696,240 in taxes.
| Income Tax | 696,240 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.48% in the last 52 weeks. The beta is 0.90, so CTXR's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -95.48% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 6.95 |
| Relative Strength Index (RSI) | 34.91 |
| Average Volume (20 Days) | 139,287 |
Short Selling Information
The latest short interest is 670,558, so 6.82% of the outstanding shares have been sold short.
| Short Interest | 670,558 |
| Short Previous Month | 755,910 |
| Short % of Shares Out | 6.82% |
| Short % of Float | 7.39% |
| Short Ratio (days to cover) | 1.09 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.69M |
| Pretax Income | -39.78M |
| Net Income | -40.72M |
| EBITDA | -42.69M |
| EBIT | -42.69M |
| Earnings Per Share (EPS) | -$5.81 |
Full Income StatementBalance Sheet
The company has $1.10 million in cash and $204,569 in debt, giving a net cash position of $895,510 or $0.09 per share.
| Cash & Cash Equivalents | 1.10M |
| Total Debt | 204,569 |
| Net Cash | 895,510 |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 68.92M |
| Book Value Per Share | 8.46 |
| Working Capital | -26.48M |
Full Balance SheetCash Flow
| Operating Cash Flow | -26.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -26.79M |
| FCF Per Share | -$2.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |